LUNESTA(R) Next-Day Function And Discontinuation Data From A Long-Term 12-Week Study In Elderly Patients Presented At ECNP
Sep 8th 2008Drug InformationSeniors
Sepracor Inc. (Nasdaq: SEPR) announced the presentation of LUNESTA ® brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. The poster presentations reflected results from a 12-week, double-blind, randomized safety and efficacy study of 388 elderly patients (65-85 years of age) who were administered either LUNESTA 2 mg or placebo nightly.
More: continued here